Together we will beat cancer

Donate

Dr Iain Frame appointed CEO of the National Cancer Research Institute

Dr Iain Frame has been appointed as the new CEO of the National Cancer Research Institute (NCRI).

Read More

Big data analysis predicts risk of radiotherapy side effects

Analysing big data to predict men’s risk of side effects could help personalise radiotherapy treatment for prostate cancer.

Read More

Test could diagnose oesophageal cancer 8 years earlier

A new genetic test could help diagnose oesophageal cancer up to 8 years before symptoms appear in people at a high risk of the disease.

Read More

Test could diagnose oesophageal cancer 8 years earlier

A new genetic test could help diagnose oesophageal cancer up to 8 years before symptoms appear in people at a high risk of the disease.

Read More

Scientists exploit leaks in blood brain barrier to treat glioblastoma

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma.

Read More

Low testosterone levels linked to reduced risk of prostate cancer

Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer.

Read More

More women than men are diagnosed with bowel cancer as an emergency despite extra GP visits

More than a third of women with bowel cancer in England were diagnosed after an emergency hospital visit compared to less than a third of men.

Read More

The NCRI partnership launches new five-year strategy to accelerate progress in cancer research

The National Cancer Research Institute (NCRI) launches its new five-year strategy today to accelerate progress in cancer research through collaboration.

Read More

Researchers find key to drug resistant bowel cancer

Blocking a molecule could bypass bowel cancer’s defence against the drug cetuximab, according to new research presented at the NCRI Cancer Conference.

Read More

Marker for aggressive prostate cancer doubles-up as a drug target

Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer.

Read More